Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium

LI Yuanyuan; YU Feng

doi:10.3969/j.issn.1006-0111.2014.06.005

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 32 Issue 6

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2014 > 32(6): 416-418,452

LI Yuanyuan, YU Feng. Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005

Citation:

LI Yuanyuan, YU Feng. Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005

Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium

doi: 10.3969/j.issn.1006-0111.2014.06.005

Depamt, emt pf Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Received Date: 2013-07-21
Rev Recd Date: 2013-12-02

Abstract

Objective To offer reference to reasonable clinical use of piperacillin sodium sodium-tazobactam sodium. Methods We reviewed pharmacokinetic/ pharmacodynamic studies, clinical trails and implementation of piperacillin sodium-tazobactam sodium alternative dosing regimen in recent. Results The alternative dosing regimens, prolonged and continuous infusion, could maximise the likelihood of achieving desirable pharmacodynamic targets and improve clinical effectiveness. Conclusion It's needed to improve the strategies of alternative dosing regimens for clinical practice.
- piperacillin sodium-tazobactam sodium,
- alternative dosing regimen,
- prolongrd infusion,
- continuous infusion

References

[1]	Gin A, Dilay L, Karlowsky JA, et al. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination[J].Expert Rev Antiinfect Ther, 2007, 5(3): 365-383.
[2]	Niederman MS, Craven D, Bonten M, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia[J].Am J Respir Crit Care Med, 2005, 171(4): 388-416.
[3]	Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the society of infectious diseases pharmacists[J].Pharmacotherapy, 2006, 26(9): 1320-1332.
[4]	Kim A, Sutherland CA, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?[J].Pharmacotherapy, 2007, 27(11): 1490-1497.
[5]	Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore[J].Clin Infect Dis, 2007, 44(1): 79-86.
[6]	叶龙强, 蔡挺. 蒙特卡罗药动药效学模型在优化抗菌药物给药方案中的应用[J].现代实用医学, 2009, 21(1): 5-6,36.
[7]	DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from the United States intensive care units in 2004[J].Pharmacotherapy, 2007, 27(3): 333-342.
[8]	Rotschafer JC, Ullman M. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients[J].Ann Pharmacother, 2009, 43(11): 1887-1889.
[9]	Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing[J].Clin Ther, 2002, 24(7): 1090-1104.
[10]	Roberts JA. Relevance of pharmacokinetics to antibiotic dosing in critically ill patients[J].Curr Pharm Biotechnol, 2011, 12(12): 1981-1982.
[11]	Roberts JA, Kirkpatrick CM, Roberts MS, et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis[J].Int J Antimicrob Agents, 2010, 35(2): 156-163.
[12]	Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis—bolus versus continuous administration?[J].Crit Care Med, 2009, 37(3): 926-933.
[13]	Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients[J].Int J Antimicrob Agents, 2006, 28(2): 122-127.
[14]	Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms[J].Int J Antimicrob Agents, 2005, 26(2): 114-119.
[15]	蔡挺, 叶龙强. 3种β-内酰胺类抗菌药物延长及持续输注对产ESBLs细菌的药效学研究[J].中华医院感染学杂志, 2010, 20(14): 2110-2113.
[16]	Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection[J].J Antimicrob Chemother, 2005, 56(2): 388-395.
[17]	Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data[J].J Antimicrob Chemother, 2011, 66(2): 343-349.
[18]	Koomanachai P, Bulik CC, Kuti JL, et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States[J].Clin Ther, 2010, 32(4): 766-779.
[19]	Shea KM, Cheatham SC, Wack MF, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients[J].Int J Antimicrob Agents, 2009, 34(5): 429-433.
[20]	Cockerill F.Performance Standards for Antimicrobial susceptibility testing: twenty-second informational supplement[M]. Colorado:Clinical and Laboratory Standards Institute, 2012.
[21]	Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia[J].Clin Ther, 2009, 31(11): 2765-2778.
[22]	Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients[J].Int J Antimicrob Agents, 2013, 41(1): 52-56.
[23]	Patel N, Scheetz MH, Drusano GL, et al. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients[J].Antimicrob Agents Chemother, 2010, 54(1): 460-465.
[24]	Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics[J].Crit Care Med, 2009, 37(6): 2071-2078.
[25]	Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital[J].Pharmacotherapy, 2002, 22(4): 471-483.
[26]	Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study[J].Am J Health Syst Pharm, 2003, 60(22): 2321-2327.
[27]	Lodise TP, Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy[J].Clin Infect Dis, 2007, 44(3): 357-363.
[28]	Yost RJ, Cappelletty DM. The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study[J]. Pharmacotherapy, 2011, 31(8): 767-775.
[29]	叶龙强, 蔡挺, 金雨虹, 等. 延长哌拉西林/他唑巴坦输注时间治疗革兰阴性杆菌感染的临床研究[J].中华医院感染学杂志, 2011, 21(16): 3476-3479.
[30]	黄永婵, 庞晓军. 延长哌拉西林他唑巴坦给药时间法治疗铜绿假单胞菌感染的临床研究[J].广西医科大学学报, 2012, 29(3): 381-383.
[31]	Patel GW,Patel N, Lat A,et al.Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections[J].Diagn Microbiol Infect Dis, 2009, 64(2): 236-240.
[32]	Xamplas RC,Itokazu GS,Glowacki RC,et al.Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital[J].Am J Health Syst Pharm, 2010, 67(8): 622-628.
[33]	Heinrich LS, Tokumaru S, Clark NM, et al. Development and implementation of a piperacillin-tazobactam extended infusion guideline[J].J Pharm Pract, 2011, 24(6): 571-576.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2622) PDF downloads(232) Cited by()

Proportional views

Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium

Depamt, emt pf Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China

Received Date: 2013-07-21

Rev Recd Date: 2013-12-02

Key words:

Abstract: Objective To offer reference to reasonable clinical use of piperacillin sodium sodium-tazobactam sodium. Methods We reviewed pharmacokinetic/ pharmacodynamic studies, clinical trails and implementation of piperacillin sodium-tazobactam sodium alternative dosing regimen in recent. Results The alternative dosing regimens, prolonged and continuous infusion, could maximise the likelihood of achieving desirable pharmacodynamic targets and improve clinical effectiveness. Conclusion It's needed to improve the strategies of alternative dosing regimens for clinical practice.

HTML

Reference (33)

[1]	Gin A, Dilay L, Karlowsky JA, et al. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination[J].Expert Rev Antiinfect Ther, 2007, 5(3): 365-383.
[2]	Niederman MS, Craven D, Bonten M, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia[J].Am J Respir Crit Care Med, 2005, 171(4): 388-416.
[3]	Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the society of infectious diseases pharmacists[J].Pharmacotherapy, 2006, 26(9): 1320-1332.
[4]	Kim A, Sutherland CA, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?[J].Pharmacotherapy, 2007, 27(11): 1490-1497.
[5]	Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore[J].Clin Infect Dis, 2007, 44(1): 79-86.
[6]	叶龙强, 蔡挺. 蒙特卡罗药动药效学模型在优化抗菌药物给药方案中的应用[J].现代实用医学, 2009, 21(1): 5-6,36.
[7]	DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from the United States intensive care units in 2004[J].Pharmacotherapy, 2007, 27(3): 333-342.
[8]	Rotschafer JC, Ullman M. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients[J].Ann Pharmacother, 2009, 43(11): 1887-1889.
[9]	Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing[J].Clin Ther, 2002, 24(7): 1090-1104.
[10]	Roberts JA. Relevance of pharmacokinetics to antibiotic dosing in critically ill patients[J].Curr Pharm Biotechnol, 2011, 12(12): 1981-1982.
[11]	Roberts JA, Kirkpatrick CM, Roberts MS, et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis[J].Int J Antimicrob Agents, 2010, 35(2): 156-163.
[12]	Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis—bolus versus continuous administration?[J].Crit Care Med, 2009, 37(3): 926-933.
[13]	Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients[J].Int J Antimicrob Agents, 2006, 28(2): 122-127.
[14]	Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms[J].Int J Antimicrob Agents, 2005, 26(2): 114-119.
[15]	蔡挺, 叶龙强. 3种β-内酰胺类抗菌药物延长及持续输注对产ESBLs细菌的药效学研究[J].中华医院感染学杂志, 2010, 20(14): 2110-2113.
[16]	Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection[J].J Antimicrob Chemother, 2005, 56(2): 388-395.
[17]	Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data[J].J Antimicrob Chemother, 2011, 66(2): 343-349.
[18]	Koomanachai P, Bulik CC, Kuti JL, et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States[J].Clin Ther, 2010, 32(4): 766-779.
[19]	Shea KM, Cheatham SC, Wack MF, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients[J].Int J Antimicrob Agents, 2009, 34(5): 429-433.
[20]	Cockerill F.Performance Standards for Antimicrobial susceptibility testing: twenty-second informational supplement[M]. Colorado:Clinical and Laboratory Standards Institute, 2012.
[21]	Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia[J].Clin Ther, 2009, 31(11): 2765-2778.
[22]	Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients[J].Int J Antimicrob Agents, 2013, 41(1): 52-56.
[23]	Patel N, Scheetz MH, Drusano GL, et al. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients[J].Antimicrob Agents Chemother, 2010, 54(1): 460-465.
[24]	Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics[J].Crit Care Med, 2009, 37(6): 2071-2078.
[25]	Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital[J].Pharmacotherapy, 2002, 22(4): 471-483.
[26]	Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study[J].Am J Health Syst Pharm, 2003, 60(22): 2321-2327.
[27]	Lodise TP, Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy[J].Clin Infect Dis, 2007, 44(3): 357-363.
[28]	Yost RJ, Cappelletty DM. The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study[J]. Pharmacotherapy, 2011, 31(8): 767-775.
[29]	叶龙强, 蔡挺, 金雨虹, 等. 延长哌拉西林/他唑巴坦输注时间治疗革兰阴性杆菌感染的临床研究[J].中华医院感染学杂志, 2011, 21(16): 3476-3479.
[30]	黄永婵, 庞晓军. 延长哌拉西林他唑巴坦给药时间法治疗铜绿假单胞菌感染的临床研究[J].广西医科大学学报, 2012, 29(3): 381-383.
[31]	Patel GW,Patel N, Lat A,et al.Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections[J].Diagn Microbiol Infect Dis, 2009, 64(2): 236-240.
[32]	Xamplas RC,Itokazu GS,Glowacki RC,et al.Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital[J].Am J Health Syst Pharm, 2010, 67(8): 622-628.
[33]	Heinrich LS, Tokumaru S, Clark NM, et al. Development and implementation of a piperacillin-tazobactam extended infusion guideline[J].J Pharm Pract, 2011, 24(6): 571-576.

Message Board

Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium

doi: 10.3969/j.issn.1006-0111.2014.06.005

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views